P-5-P (pyridoxal-5-phosphate)

Pyridoxal-5′-Phosphate (P-5-P): A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Common Forms

Pyridoxal-5′-phosphate (abbreviated PLP or P-5-P) is the principal biologically active coenzyme form of vitamin B6. Vitamin B6 is a water-soluble vitamin that is naturally present in many foods, added to others, and available as a dietary supplement. It is the generic name for six compounds (vitamers) with vitamin B6 activity: pyridoxine, an alcohol; pyridoxal, an aldehyde; and pyridoxamine, which contains an amino group; and their respective 5′-phosphate esters.

Vitamin B6 is a generic term that refers to the pyridine-based compounds pyridoxine, 4-pyridoxic acid, pyridoxamine, pyridoxal, and their phosphorylated derivatives. Pyridoxal-5′-phosphate (PLP) is the biologically active form and serves as a cofactor for more than 140 different enzyme reactions, representing 4% of all known catalytic activity.

Structurally, PLP is the 5′-phosphate ester of pyridoxal, a 4-formyl substituted pyridine derivative. After determination of the structure of vitamin B6 in 1939, György named the vitamin pyridoxine due to its structural homology to pyridine. The aldehyde group at position 4 of the pyridine ring is chemically essential to PLP's catalytic function, enabling the formation of Schiff base (aldimine) intermediates with amino acid substrates. The PLP cofactor, derived from vitamin B6, is widely distributed in nature and has significant latitude in catalytic diversity.

Common Names and Synonyms

• Pyridoxal-5′-phosphate (IUPAC-aligned systematic name)
• Pyridoxal phosphate (abbreviated PLP)
• P-5-P, P5P (common supplement abbreviations)
• Codecarboxylase (historical biochemical term)
• Pyridoxal 5′-monophosphate

Natural Dietary Sources

Dietary sources of vitamin B6 include cereals, beans, vegetables, liver, meat, and eggs. Food sources of vitamin B-6 include poultry, fish, potatoes, chickpeas, bananas, and fortified cereals. The primary forms of vitamin B6 in meats are esters, and the dominant plant source is pyridoxine, which is less bioavailable. Animal-sourced foods thus tend to provide a higher proportion of the phosphorylated, more directly utilizable forms of B6.

Common Supplement Preparations

Vitamin B-6 can also be taken as a supplement, typically as an oral capsule, tablet, or liquid. P5P supplements are available in various forms, including capsules, tablets, and powder formulations. In clinical and research contexts, PLP has also been prepared in effervescent formulations for neonatal administration; administration to neonates is difficult, as P5P has low water-solubility, a phenomenon that is characterized by the yellowish solid residue observed on the dissolution device. Because PLP is sensitive to light-induced degradation, clinical specimens containing it must be protected from light, and pharmaceutical formulations accordingly must address photo-stability. Pyridoxine is the usual vitamin in multivitamin supplements. P-5-P as a stand-alone supplement offers the active, unconverted form directly.

2. Historical and Traditional Context

Discovery and Isolation

The history of PLP begins with the recognition of vitamin B6 itself, which emerged from nutritional research in the 1930s. In the 1930s, Rudolf Peters showed that young rats kept on a semi-synthetic diet with added thiamin and riboflavin but no other supplement developed "rat acrodynia," a condition characterized by severe cutaneous lesions. In 1934, Paul György showed that the factor which cured "rat acrodynia" was vitamin B6. Other studies soon showed that vitamin B6 deficiency produced convulsions in rats, pigs, and dogs, and a microcytic anemia in certain animals.

Vitamin B6 (pyridoxine) was discovered in 1934 by György and colleagues, and the active compound was first isolated by Samuel Lepovsky (1901–1984) of the University of California, Berkeley, in 1938. Folkers and his Merck colleague Stanton Harris determined the structure of pyridoxine in 1939, simultaneously with Kuhn in Germany.

Esmond Snell developed a microbiological growth assay in 1942 that led to the characterization of pyridoxamine, the aminated product of pyridoxine, and pyridoxal, the formyl derivative of pyridoxine. The coenzyme form, pyridoxal 5′-phosphate, was identified in the mid-20th century as the metabolically active species—distinct from the dietary precursor form pyridoxine—following investigations into the enzymatic mechanisms of transamination and decarboxylation.

Since microbiological assays pointed towards several forms of the vitamin B6-active compound, the enzymatic conversion of various forms of vitamin B6 into pyridoxal 5′-phosphate (pyridoxal-P), the active form of the vitamin in vivo, has been intensively investigated. Pyridoxine, pyridoxamine, pyridoxal, and their 5′-phosphate esters are now recognized as principal vitamin B6 compounds.

Early Clinical Recognition

In the early 1950s, seizures were observed in infants as a result of severe vitamin B6 deficiency caused by an error in the manufacture of infant formula. This event brought clinical awareness to the role of adequate PLP in neonatal neurological function and catalyzed research into B6-responsive seizure disorders. No distinct ethnobotanical or traditional medicinal tradition specifically used isolated PLP, as PLP is not present in isolation in plant or animal foods and was not extractable in pure form prior to modern chemistry. Traditional healers would have indirectly administered PLP precursors through food sources such as liver, yeast, and legumes, long recognized empirically for their restorative properties in dermatological and neurological conditions associated with nutritional deficiency.

3. Biochemistry: Key Constituents, Metabolism, and Active Form

Metabolic Conversion to PLP

After absorption, pyridoxine, pyridoxamine, and pyridoxal are transported into hepatic cells by facilitated diffusion. Pyridoxal kinase phosphorylates pyridoxal, pyridoxine, and pyridoxamine into PLP, PNP, and PMP, respectively. Subsequently, PMP and PNP are converted into PLP by pyridoxine (pyridoxamine) phosphate oxidase found exclusively in the liver, kidney, and brain. Vitamin B6 is predominantly excreted in the urine as 4-pyridoxic acid, with its active forms undergoing renal tubular reabsorption; approximately 3% of ingested vitamin B6 is eliminated via feces.

Deficiencies can occur in people with mutations of pyridoxal kinase (PLK) or pyridoxine 5′-phosphate oxidase (PNPOx), as well as in individuals who are pregnant, have kidney disease, are severely malnourished, or have malabsorption.

Enzymatic Mechanisms of Action

The versatility of reactions catalyzed by pyridoxal 5′-phosphate (PLP) enzymes is largely due to the chemistry of their extraordinary catalyst. PLP is necessary for many reactions involving amino acids. Reaction specificity is controlled by the orientation of the external aldimine intermediate that is formed upon addition of the amino acidic substrate to the coenzyme. The breakage of a specific bond of the external aldimine gives rise to a carbanionic intermediate. From this point, the different reaction pathways diverge leading to multiple activities: transamination, decarboxylation, racemization, elimination, and synthesis.

Beyond classic amino acid reactions, PLP plays an atypical but essential structural and catalytic role in glycogen metabolism. In glycogen phosphorylases, the phosphate of the cofactor pyridoxal 5′-phosphate acts as a general acid and protonates the substrate phosphate, functioning as a proton shuttle.

PLP also participates in hormonal regulation at the gene-expression level. Pyridoxal phosphate has a role in controlling the action of hormones that act by binding to a nuclear receptor protein and modulating gene expression. Such hormones include androgens, estrogens, progesterone, glucocorticoids, calcitriol (the active metabolite of vitamin D), retinoic acid and other retinoids, and thyroid hormone. Pyridoxal phosphate reacts with a lysine residue in the receptor protein and displaces the hormone–receptor complex from DNA binding, so terminating the hormone action.

Neurotransmitter Synthesis

Pyridoxal 5′-phosphate (PLP) is a required coenzyme for the biosynthesis of several neurotransmitters, including GABA, dopamine, norepinephrine, and serotonin. Dopamine, serotonin, epinephrine, norepinephrine, and γ-aminobutyric acid (GABA) all require pyridoxine for their production. Given that vitamin B6 concentrations in the brain are about 100 times higher than levels in the blood, it is not surprising that vitamin B6 deficiency has neurologic effects.

One-Carbon Metabolism and Homocysteine Regulation

Cardiovascular applications of P5P supplementation focus primarily on its role in homocysteine metabolism. Elevated homocysteine levels are associated with increased cardiovascular disease risk, and P5P is essential for the transsulfuration pathway that converts homocysteine to cysteine. The metabolism of homocysteine is closely linked to the availability of B vitamins such as folate, vitamin B6, and vitamin B12.

Heme and Porphyrin Synthesis

Vitamin B6 is critical in transamination and decarboxylation, the initial steps of porphyrin synthesis. PLP-dependent enzymes catalyze the condensation of glycine and succinyl-CoA to form delta-aminolevulinic acid, the first committed step of heme biosynthesis, which explains why severe B6 deficiency produces microcytic anemia.

Immune Regulation via Tryptophan-Kynurenine Pathway

Several enzymatic reactions in the tryptophan-kynurenine pathway are dependent on vitamin B6 coenzyme, pyridoxal 5′-phosphate (PLP). This pathway is known to be activated during pro-inflammatory immune responses and plays a critical role in immune tolerance of the fetus during pregnancy. Key intermediates in the tryptophan-kynurenine pathway are involved in the regulation of immune responses. Several tryptophan derivatives have been found to induce the death (apoptosis) or block the proliferation of certain types of immune cells, such as lymphocytes (in particular T-helper 1). They can also inhibit the production of pro-inflammatory cytokines.

Interleukin-2 Production

Pyridoxine influences cognitive development due to its involvement in neurotransmitter synthesis and immune function because of its role in interleukin-2 (IL-2) production.

4. Scientific Evidence by Area of Use

4.1 Vitamin B6 Deficiency and Its Clinical Manifestations

PLP status is clinically assessed by measuring plasma PLP concentrations. Levels for fasting individuals falling in the range of 3 to 30 mcg/L for pyridoxic acid (PA) and 5 to 50 mcg/L for pyridoxal 5-phosphate (PLP) are indicative of adequate nutrition.

Deficiency affects the blood, skin, and nervous system. The skin changes are indistinguishable from pellagra, probably due to the close interaction of niacin and pyridoxine. Pyridoxine-deficient peripheral neuropathy is seen primarily in patients on isoniazid or hydralazine, and it is characterized by sensory loss in distal limbs, weakness, and reflex changes. Patients describe burning feet and painful paresthesias. CNS manifestations include depression, irritability, and confusion.

Severely deficient adults may present with seborrheic dermatitis, microcytic anemia, and seizures. Groups at particular risk include individuals with disorders that affect digestive nutrient absorption (e.g., celiac disease), kidney function, or liver health. Pregnancy, autoimmune diseases, alcohol misuse, obesity, and smoking can also contribute to a B6 deficiency. A large cross-sectional study of UK adults found that smokers had significantly lower plasma PLP concentrations than non-smokers (p < 0.001).

4.2 Pyridoxamine 5′-Phosphate Oxidase (PNPO) Deficiency and Vitamin-Responsive Epilepsy

This is the clinical area where PLP supplementation has the most clearly established therapeutic role. Pyridoxamine-5′-phosphate oxidase (PNPO) deficiency is an autosomal recessive pyridoxal 5′-phosphate (PLP)-vitamin-responsive epileptic encephalopathy. The emerging feature of PNPO deficiency is the occurrence of refractory seizures in the first year of life. This deficiency manifests within hours of birth as a severe seizure disorder that does not respond to anticonvulsant drugs and can be fatal, if untreated. Seizures can cease with the administration of the active form of B6, pyridoxal 5′-phosphate (PLP), but are not always responsive to pyridoxine (PN).

A scoping review of 87 confirmed PNPO cases found that all patients who received PLP (n = 36) showed a clinical response, with a complete dramatic PLP response with seizure cessation observed in 61% of patients. The treatment dose of PLP has largely been empirical, guided by clinical response, with reported doses varying from 30 to 60 mg/kg/day. PLP is not licensed as a drug for the treatment of epilepsy outside of Asia. Evidence quality in this area is predominantly case series and case reports due to the rarity of the condition, but the clinical signal is consistent and well-established enough that major pediatric neurology guidelines recommend PLP as part of the diagnostic and treatment algorithm for neonatal-onset seizures.

Pyridoxal phosphate-responsive seizures (sometimes called PNPO deficiency) is a condition in which repeated seizures typically begin within the first two weeks of life. In approximately 10 percent of individuals with PNPO deficiency, the seizures have a later onset, beginning after the first month of life.

A significant safety concern has been documented at high treatment doses: one reported case involved an eight-year-old boy with PNPO deficiency who developed cirrhosis while being treated with high-dose PLP. Despite extensive investigation, no cause other than PLP therapy could be identified for the cirrhosis.

4.3 Nausea and Vomiting of Pregnancy (NVP)

Vitamin B6, principally in the form of pyridoxine, is among the most studied interventions for nausea and vomiting of pregnancy. The most common prescription product combines doxylamine (an antihistamine) with pyridoxine. The active treatment in one pivotal RCT was a tablet containing both doxylamine 10 mg and pyridoxine 10 mg taken between 2 and 4 times per day for 14 days depending on symptoms, versus an identical placebo, with the primary outcome being improvement in nausea and vomiting symptom scores using the 13-point pregnancy unique quantification of emesis scale between baseline and 14 days. There is a trend towards efficacy for nausea and vomiting symptoms with doxylamine-pyridoxine compared with placebo, but the statistical significance of the difference depends on the method of handling missing data and the magnitude of the difference suggests that there is no clinically important benefit employing the prespecified minimal clinically important difference.

More specific to PLP, a 2024 study investigated circulating PLP levels. Although vitamin B6 supplementation has been shown to alleviate NVP, the physiological significance of its active form, pyridoxal 5′-phosphate (PLP), and its association with the natural course of symptom resolution remain unclear. This study enrolled 352 pregnant women with NVP symptoms at ≤12 gestational weeks. The exposure variable was serum PLP concentration, categorized into quartiles. The primary outcome was the time to spontaneous NVP resolution, defined by a "7-day confirmation criterion," with cumulative remission rates compared across quartiles using Kaplan–Meier analysis. Overall, the evidence base for NVP specifically uses pyridoxine rather than PLP directly; the assumption is that pyridoxine is converted to PLP in vivo, but head-to-head trials comparing PLP versus pyridoxine for NVP are lacking.

4.4 Cardiovascular Disease and Homocysteine

A randomized, double-blind, placebo-controlled trial evaluated the effect of active B vitamin supplementation including P5P on cardiovascular risk markers. In this trial, 54 patients aged 40–75 with elevated homocysteine and moderate LDL-C levels were divided based on MTHFR, MTR, and MTRR genetic polymorphisms, and over six months they received either a combination of methylfolate, P5P, and methylcobalamin, or a placebo. Methylfolate, P5P, and methylcobalamin supplementation tailored to genetic profiles effectively reduced homocysteine and LDL-C levels in patients with specific MTHFR, MTR, and MTRR polymorphisms, particularly with homozygous minor allele polymorphisms. Some studies suggest that P5P supplementation, particularly when combined with other B vitamins, may help reduce homocysteine levels in individuals with elevated levels.

However, it should be noted that, although homocysteine-lowering by B vitamins is well-established, clinical trials have not uniformly demonstrated that homocysteine reduction translates into reduced cardiovascular events. The evidence linking PLP status to cardiovascular inflammation is observational. A community-based cohort study (n=2,229) found that low vitamin B-6 status, based on plasma concentrations of pyridoxal-5-phosphate (PLP), has been identified in inflammatory diseases, including cardiovascular disease, rheumatoid arthritis, inflammatory bowel disease, and diabetes. Geometric mean plasma PLP concentrations were lower in the highest tertile category of inflammation score relative to the lowest (61 vs. 80 nmol/L; P-trend < 0.0001). These associations are cross-sectional and cannot establish causality.

4.5 Mental Health: Depression and Mood

Evidence regarding the associations of pyridoxal 5′-phosphate level in plasma and dietary intake of vitamin B6 with depression risk is scarce. A large cross-sectional study using NHANES 2005–2010 data examined this relationship. This study included data from two independent samples of 12,716 and 11,967 individuals (aged ≥ 20 years) participating in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2010. In the multivariable model, the highest quarter of dietary intake of vitamin B6 was associated with a significantly lower risk of depression compared to the lowest quarter (OR = 0.63, 95% CI: 0.50, 0.79, p < 0.001). Similarly, the highest quartile of plasma PLP levels was linked to a reduced risk of depression compared to the lowest quartile (OR = 0.76, 95% CI: 0.62, 0.93, p < 0.01). The cross-sectional design, however, prevents causal inference. Plasma PLP may be depleted by inflammation or other factors that independently drive depression.

4.6 Cognitive Function and Neurological Health

Vitamin B6 deficiency has been linked to cognitive impairment in human brain disorders for decades. Still, the molecular mechanisms linking vitamin B6 to these pathologies remain poorly understood, and whether vitamin B6 supplementation improves cognition is unclear.

A PDXP and age-dependent decline of PLP levels in the murine hippocampus provides a rationale for the development of PDXP inhibitors. Population studies indicate that low vitamin B6 levels are common among older people and suggest that vitamin B6 deficiency may influence memory performance and may contribute to age-related cognitive decline. Vitamin B6 deficiency is also associated with other conditions characterized by impaired learning and memory, including neuropsychiatric disorders, Alzheimer's disease, and inflammation.

On the clinical intervention side, evidence is mixed. A one-year randomized, double-blind, placebo-controlled trial in 253 elderly (≥65 years) adults with elevated homocysteine levels found that B vitamin supplementation (1,000 μg/day of folate, 10 mg/day of vitamin B6, and 500 μg/day of vitamin B12) did not improve measures of cognitive function, including memory, despite lowering homocysteine levels. In contrast, another trial found that vitamin B6 supplementation (20 mg/day of pyridoxine hydrochloride) for three months improved memory, especially long-term memory, in 38 healthy elderly men (70–79 years) compared to 38 men of similar age who received a placebo. Overall, clinical trial evidence for cognition benefits is inconsistent, and studies specifically using PLP rather than pyridoxine are scarce.

4.7 Premenstrual Syndrome (PMS)

High-dose B6 has been studied, with mixed results, for alleviating symptoms of PMS, particularly mood-related symptoms. PLP's role in PMS has been investigated via measurement of plasma PLP in affected versus unaffected women. A 1986 study published in PubMed measured plasma pyridoxal 5′-phosphate (PLP) in 210 healthy premenopausal women and related results to their experience of the premenstrual syndrome (PMS). Plasma PLP values were similar in the two groups (mean values of 39.59 ± 22.95 and 40.56 ± 23.33 nmol/L respectively). The authors concluded that pyridoxine status, as measured by plasma PLP levels, is not altered in women with PMS and that pyridoxine deficiency is unlikely to contribute to the occurrence of this syndrome. P5P supplementation has been studied for its potential benefits in PMS, with some research suggesting that vitamin B6 supplementation may help reduce symptoms such as mood changes, bloating, and breast tenderness. However, the evidence for P5P specifically in PMS is limited compared to studies using pyridoxine.

4.8 Inflammation

Observational data consistently show an inverse association between plasma PLP and markers of systemic inflammation. The analysis of data from a cohort of 891 elderly adults participating in the Framingham Heart Study indicated that low vitamin B6 status was associated with higher CRP levels; this association was independent of plasma homocysteine. In this study, vitamin B6 status was assessed by measuring plasma levels of pyridoxal 5′-phosphate (PLP). PLP is the active form of the vitamin and considered to be a good indicator of long-term body stores. More recently, plasma PLP levels were inversely associated with CRP levels in a cohort of older Puerto Rican adults.

Whether these associations represent a causal protective role of PLP against inflammation—or whether inflammation depletes circulating PLP—remains a key unresolved question. A low circulating level of vitamin B6 is a risk factor for cardiovascular disease and may also be related to rheumatoid arthritis.

4.9 Immune Function

There is evidence to suggest that adequate vitamin B6 intake is important for optimal immune system function, especially in older individuals. In the Framingham Offspring study, those with the lowest levels of pyridoxal 5′-phosphate (PLP), the active form of vitamin B6, had the highest levels of chronic inflammation, whereas those with highest levels of PLP had lower levels. Mechanistically, PLP participates in interleukin-2 signaling and tryptophan-kynurenine pathway regulation, both critical to lymphocyte function, though direct clinical trials testing PLP supplementation as an immune-modulating intervention in healthy adults are limited.

4.10 Drug-Induced B6 Depletion

A clinically important and well-documented application involves the use of B6 (typically as pyridoxine, though PLP is the active species) to prevent neuropathy induced by certain medications. Deficiencies have been observed with the usage of certain drugs such as isoniazid, penicillamine, benserazide, and carbidopa. Certain medications (cycloserine, hydralazine, isoniazid, D-penicillamine, pyrazinamide, phenelzine, thiamphenicol, and L-dopa) can alter vitamin B6 status by covalently binding to the carbonyl groups of PLP or PL. Pyridoxine improves the microcytic anemia of alcoholics as well as the anemia associated with pyridoxine-responsive seizures in infants.

5. Body Systems Associated with PLP

• Nervous system: Neurotransmitter synthesis (GABA, dopamine, serotonin, norepinephrine, epinephrine); seizure threshold; peripheral nerve integrity.
• Cardiovascular system: Homocysteine metabolism via transsulfuration; inflammatory marker modulation (CRP).
• Hematopoietic system: Heme/porphyrin biosynthesis; hemoglobin production; prevention of microcytic anemia.
• Immune system: Tryptophan-kynurenine pathway regulation; IL-2 production; lymphocyte function.
• Endocrine system: Steroid hormone receptor modulation (estrogen, androgens, progesterone, glucocorticoids, calcitriol, thyroid hormone).
• Musculoskeletal system: Glycogen phosphorylase activity; energy supply to muscle tissue.
• Hepatic system: Site of primary interconversion of B6 vitamers to PLP; high-dose PLP has been associated with hepatotoxicity in at least one documented pediatric case.

6. Dosage Forms and Doses Reported in Clinical Studies

The following doses are reported as they appeared in source documents and are not recommendations.

• Nausea and vomiting of pregnancy (NVP): The active treatment in one pivotal RCT was a tablet containing both doxylamine 10 mg and pyridoxine 10 mg, taken between 2 and 4 times per day for 14 days.
• PNPO deficiency (neonatal epilepsy): The treatment dose of PLP has largely been empirical, guided by clinical response, with reported doses varying from 30 to 60 mg/kg/day.
• Cognitive function in elderly men: Vitamin B6 supplementation at 20 mg/day of pyridoxine hydrochloride for three months improved memory in 38 healthy elderly men aged 70–79 years.
• Homocysteine reduction / cardiovascular risk: One trial used B vitamin supplementation comprising 1,000 μg/day of folate, 10 mg/day of vitamin B6, and 500 μg/day of vitamin B12 in 253 elderly adults over one year.
• Rheumatoid arthritis: A double-blind, placebo-controlled trial in 33 patients with rheumatoid arthritis reported that supplementation with 30 mg/day of pyridoxine for 30 days corrected the vitamin B6 deficiency.
• B vitamin combination for homocysteine/LDL (P5P specifically): A six-month randomized controlled trial in 54 patients used a combination of methylfolate, P5P, and methylcobalamin.
• P5P supplement equivalence note: One tablet contains 39.18 mg of pyridoxal 5-phosphate monohydrate, which is molecularly equivalent to the activity of 25 mg of pyridoxine.

7. Safety Considerations and Drug Interactions

7.1 Upper Tolerable Intake Levels

The NIH (U.S.) upper tolerable intake level (UL) is 100 mg/day for adults; EFSA (EU) set a conservative UL of 12 mg/day—both count total B6 intake from all sources. These limits apply to total vitamin B6 regardless of form. The wide discrepancy between U.S. and European ULs reflects methodological differences in how regulators weighed the neuropathy evidence.

7.2 Peripheral Neuropathy

This vitamin is unique in that either deficiency or excess can cause peripheral neuropathy. Both vitamin B6 deficiency and high B6 intake have been described as risk factors for developing peripheral neuropathy (PN). Higher vitamin B6 levels, which usually occur following the taking of nutritional supplements, may lead to the development of a predominantly, if not exclusively, sensory neuropathy of the axonal type. After pyridoxine discontinuation, such patients subjectively report improved symptoms.

The neuropathy risk is more extensively documented for pyridoxine (the non-phosphorylated form) than for PLP directly. Pyridoxal-5-phosphate (PLP/P5P) is the active coenzyme form; it is rarely the focus of neuropathy case clusters, though official upper limits apply to total B6 from all forms. The postulated reason is that excess free pyridoxine may interfere with B6 metabolism in neurons, whereas PLP is already in the active state and tightly regulated.

7.3 Hepatotoxicity at High Doses in PNPO Deficiency

At the very high doses used in pediatric PNPO deficiency treatment, hepatotoxicity has been documented. One case involved an eight-year-old boy with PNPO deficiency who developed cirrhosis while being treated with high-dose PLP. Despite extensive investigation, no cause other than PLP therapy could be identified for the cirrhosis. This case underscores the importance of monitoring liver function during high-dose PLP therapy.

7.4 Drug Interactions

Cycloserine: Cycloserine (Seromycin) is a broad-spectrum antibiotic used to treat tuberculosis. In combination with pyridoxal phosphate, cycloserine increases urinary excretion of pyridoxine. The urinary loss of pyridoxine might exacerbate the seizures and neurotoxicity associated with cycloserine. Pyridoxine supplements can help prevent these adverse effects.

Isoniazid, hydralazine, and related drugs: Cycloserine, hydralazine, isoniazid, D-penicillamine, pyrazinamide, phenelzine, thiamphenicol, and L-dopa can alter vitamin B6 status by covalently binding to the carbonyl groups of PLP or PL.

Oral contraceptives and antiepileptics: Oral contraceptives and some antiepileptics can cause B6 deficiency by interfering with its metabolism, increasing its requirement, or enhancing its breakdown.

Theophylline and progabide: Progabide, an antiepileptic drug, and theophylline may disrupt vitamin B6 metabolism by inhibiting pyridoxal kinase.

7.5 Populations at Higher Risk of Deficiency

Patients at risk for pyridoxine deficiency include those with general malnutrition, prisoners of war, refugees, alcoholics, infants of vitamin B6-deficient mothers, and patients using isoniazid and hydralazine. Surveys of hospitalized elderly patients have shown that up to 5% may have a vitamin B6 deficiency. Among UK adults, a national dietary nutrition survey found an association between reduction in vitamin B6 intake and plasma PLP concentration and age group (p < 0.001).

7.6 Bioavailability Considerations Specific to PLP

Vitamin B6 is absorbed in the small intestine and is dephosphorylated prior to absorption. This means that dietary or supplemental PLP is hydrolyzed to free pyridoxal at the intestinal brush border before being taken up, then re-phosphorylated intracellularly in the liver. As a result, the theoretical absorption advantage of taking PLP directly—bypassing conversion—is attenuated by this intestinal dephosphorylation step. Supplements with active P-5-P are promoted to be more efficient as they don't require conversion, but the available research is limited. Clinical pharmacokinetic studies directly comparing the bioavailability of oral PLP versus pyridoxine in healthy adults are limited in number, and definitive superiority of PLP over pyridoxine in raising plasma PLP status in individuals with normal hepatic conversion capacity has not been conclusively established in large trials.

8. Summary of Evidence Strength by Indication

• PNPO deficiency / neonatal vitamin-responsive epilepsy: Evidence level — moderate-to-strong (consistent case series and small trials; PLP is the treatment of choice where pyridoxine fails). Causality well-established through genetic confirmation.
• Prevention of drug-induced B6 depletion (isoniazid, cycloserine, hydralazine): Evidence level — well-established for pyridoxine supplementation; the mechanistic rationale applies to PLP as the active coenzyme form.
• Homocysteine reduction: Evidence level — moderate for the B vitamin combination (folate + B12 + B6/PLP); clinical cardiovascular outcome benefit of homocysteine lowering itself remains debated.
• Nausea and vomiting of pregnancy: Evidence level — moderate for pyridoxine-doxylamine combination (FDA-approved); PLP-specific trials are lacking.
• Depression / mood: Evidence level — preliminary/observational (cross-sectional associations; confounding not fully excluded; no large PLP-specific RCTs).
• Cognitive function: Evidence level — inconsistent/weak (mixed RCT results; large trials show no benefit; some smaller trials show benefit in elderly).
• PMS: Evidence level — weak/mixed (some positive RCTs for pyridoxine; plasma PLP not found to differ between PMS and non-PMS women in at least one study).
• Inflammation / CRP reduction: Evidence level — observational only (inverse associations in large cohorts; intervention trials are limited).

References

• NIH Office of Dietary Supplements — Vitamin B6: Health Professional Fact Sheet
• Mayo Clinic Laboratories Pediatric Catalog — Vitamin B6 Profile (Pyridoxal 5-Phosphate and Pyridoxic Acid), Plasma
• Mayo Clinic — Vitamin B-6
• Linus Pauling Institute, Oregon State University — Vitamin B6
• Linus Pauling Institute — Cognitive Function In Depth
• Linus Pauling Institute — Inflammation
• Lu J, et al. Associations of Dietary Intake of Vitamin B6 and Plasma Pyridoxal 5′-Phosphate Level With Depression in US Adults: Findings From NHANES 2005–2010. Brain and Behavior. 2024. PMC11541856
• Friso S, et al. Plasma Pyridoxal-5-Phosphate Is Inversely Associated with Systemic Markers of Inflammation in a Population of U.S. Adults. Journal of Nutrition. PMC3374666
• Alsaeedi A, et al. Impact of lifestyle factors on dietary vitamin B6 intake and plasma pyridoxal 5′-phosphate level in UK adults: NDNS 2008–2017. British Journal of Nutrition. 2023. PMC10511679
• Jansen ECW, et al. The Role of Vitamin B6 in Peripheral Neuropathy. PMC10343656
• Randomized Controlled Trial: Methylfolate, Pyridoxal-5′-Phosphate, and Methylcobalamin Supplementation on Homocysteine and LDL Cholesterol. PMC11173557
• Clément A, et al. Phenotypic and molecular spectrum of pyridoxamine-5′-phosphate oxidase deficiency: A scoping review of 87 cases. PMC7820968
• Cirrhosis Associated with Pyridoxal 5′-Phosphate Treatment of PNPO Deficiency. PMC4241198
• MedlinePlus Genetics — Pyridoxal Phosphate-Responsive Seizures
• Combs GF Jr. A history of the isolation and identification of vitamin B(6). Annals of Nutrition and Metabolism. 2012. PubMed 23183295
• American Chemical Society — The Vitamin B Complex: A National Historic Chemical Landmark
• Harris TK, et al. Pyridoxal 5′-phosphate dependent reactions: Analyzing the mechanism of aspartate aminotransferase. PubMed 32093839
• Bertoldi M. Oxygen reactivity with pyridoxal 5′-phosphate enzymes: biochemical implications and functional relevance. PubMed 32844248
• Plasma pyridoxal 5′-phosphate in women with the premenstrual syndrome. PubMed 3957714
• Sheehan P, et al. Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis. PMC5771578
• Vitamin B6 Deficiency. StatPearls. NCBI Bookshelf. NBK470579
• Medscape — Vitamin B6: Reference Range, Interpretation, Collection and Panels
• Müller M, et al. 7,8-Dihydroxyflavone is a direct inhibitor of human and murine pyridoxal phosphatase. PMC11164532
• Association between serum PLP levels and the natural resolution of nausea and vomiting in pregnancy: a secondary analysis. PMC12926342
• ClinicalTrials.gov — Oral Pyridoxal 5′-Phosphate for the Treatment of Patients With PNPO Deficiency. NCT04706013
• Parra M, et al. Vitamin B6: A Long Known Compound of Surprising Complexity. PMC6253932